APA

Ollila T. A., Olszewski A. J., Butera J. N., Quesenberry M. I., Quesenberry P. J. & Reagan J. L. (20190304). Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. : Clinical lymphoma, myeloma & leukemia.

Chicago

Ollila Thomas A, Olszewski Adam J, Butera James N, Quesenberry Matthew I, Quesenberry Peter J and Reagan John L. 20190304. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. : Clinical lymphoma, myeloma & leukemia.

Harvard

Ollila T. A., Olszewski A. J., Butera J. N., Quesenberry M. I., Quesenberry P. J. and Reagan J. L. (20190304). Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. : Clinical lymphoma, myeloma & leukemia.

MLA

Ollila Thomas A, Olszewski Adam J, Butera James N, Quesenberry Matthew I, Quesenberry Peter J and Reagan John L. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. : Clinical lymphoma, myeloma & leukemia. 20190304.